Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.

Ponce DM, Sauter C, Devlin S, Lubin M, Gonzales AM, Kernan NA, Scaradavou A, Giralt S, Goldberg JD, Koehne G, Perales MA, Young JW, Castro-Malaspina H, Jakubowski A, Papadopoulos EB, Barker JN.

Biol Blood Marrow Transplant. 2013 May;19(5):799-803. doi: 10.1016/j.bbmt.2013.02.007. Epub 2013 Feb 14.

PMID:
23416850
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

[Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies].

Sun ZM, Liu HL, Geng LQ, Zhou CY, Wang XB, Ding KY, Tong J, Zhu WB, Liu X, Wang ZY.

Zhonghua Yi Xue Za Zhi. 2012 Jun 26;92(24):1660-4. Chinese.

PMID:
22944153
[PubMed - indexed for MEDLINE]
3.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009. Epub 2013 Mar 21.

PMID:
23523970
[PubMed - indexed for MEDLINE]
4.

Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.

Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.

Biol Blood Marrow Transplant. 2007 Jul;13(7):790-805. Epub 2007 Apr 23.

PMID:
17580257
[PubMed - indexed for MEDLINE]
5.

A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.

Shore T, Harpel J, Schuster MW, Roboz GJ, Leonard JP, Coleman M, Feldman EJ, Silver RT.

Biol Blood Marrow Transplant. 2006 Aug;12(8):868-75.

PMID:
16864057
[PubMed - indexed for MEDLINE]
6.

Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.

Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L.

Biol Blood Marrow Transplant. 2003 Jul;9(7):453-9.

PMID:
12869959
[PubMed - indexed for MEDLINE]
7.

Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.

Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG.

Biol Blood Marrow Transplant. 2011 Sep;17(9):1327-34. doi: 10.1016/j.bbmt.2011.01.007. Epub 2011 Jan 11.

PMID:
21232621
[PubMed - indexed for MEDLINE]
8.

Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.

Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M.

Leuk Lymphoma. 2012 May;53(5):901-6. doi: 10.3109/10428194.2011.631159. Epub 2012 Jan 3.

PMID:
21988645
[PubMed - indexed for MEDLINE]
9.

Double-unit cord blood transplantation after myeloablative conditioning for patients with hematologic malignancies: a multicenter phase II study in Japan.

Kai S, Wake A, Okada M, Kurata M, Atsuta Y, Ishikawa J, Nakamae H, Aotsuka N, Kasai M, Misawa M, Taniguchi S, Kato S.

Biol Blood Marrow Transplant. 2013 May;19(5):812-9. doi: 10.1016/j.bbmt.2013.02.011. Epub 2013 Feb 14.

PMID:
23416856
[PubMed - indexed for MEDLINE]
10.

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR; German Cooperative Transplant Study Group.

Ann Hematol. 2003 Jun;82(6):336-42. Epub 2003 May 1.

PMID:
12728337
[PubMed - indexed for MEDLINE]
11.

Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.

Wall DA, Carter SL, Kernan NA, Kapoor N, Kamani NR, Brochstein JA, Frangoul H, Goyal RK, Horan JT, Pietryga D, Wagner JE, Kurtzberg J; COBLT Steering Committee.

Biol Blood Marrow Transplant. 2005 Aug;11(8):637-46.

PMID:
16041314
[PubMed - indexed for MEDLINE]
12.

Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor.

Magro E, Regidor C, Cabrera R, Sanjuán I, Forès R, Garcia-Marco JA, Ruiz E, Gil S, Bautista G, Millán I, Madrigal A, Fernandez MN.

Haematologica. 2006 May;91(5):640-8.

PMID:
16670070
[PubMed - indexed for MEDLINE]
Free Article
14.

Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.

Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE.

Blood. 2003 Sep 1;102(5):1915-9. Epub 2003 May 8.

PMID:
12738676
[PubMed - indexed for MEDLINE]
Free Article
15.

Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.

Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Ballerini F, Miglino M, Varaldo R, Bacigalupo A.

Biol Blood Marrow Transplant. 2013 Jan;19(1):117-22. doi: 10.1016/j.bbmt.2012.08.014. Epub 2012 Aug 29.

PMID:
22940057
[PubMed - indexed for MEDLINE]
16.

Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S, Eapen M, Freed BM, Grimley M, Levine JE, Logan B, Moore T, Panepinto J, Parikh S, Pulsipher MA, Sande J, Schultz KR, Spellman S, Shenoy S.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1265-72. doi: 10.1016/j.bbmt.2012.01.019. Epub 2012 Feb 16.

PMID:
22343376
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.

Sanz J, Boluda JC, Martín C, González M, Ferrá C, Serrano D, de Heredia CD, Barrenetxea C, Martinez AM, Solano C, Sanz MA, Sanz GF; Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH).

Bone Marrow Transplant. 2012 Oct;47(10):1287-93. doi: 10.1038/bmt.2012.13. Epub 2012 Feb 13.

PMID:
22327127
[PubMed - indexed for MEDLINE]
18.

Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies.

Wang X, Liu H, Li L, Geng L, Ding K, Liu X, Tong J, Zhu W, Sun Z.

Eur J Haematol. 2012 Jan;88(1):39-45. doi: 10.1111/j.1600-0609.2011.01709.x. Epub 2011 Nov 15.

PMID:
21933279
[PubMed - indexed for MEDLINE]
19.

Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies.

Moscardó F, Sanz J, Senent L, Cantero S, de la Rubia J, Montesinos P, Planelles D, Lorenzo I, Cervera J, Palau J, Sanz MA, Sanz GF.

Haematologica. 2009 Jun;94(6):827-32. doi: 10.3324/haematol.2008.000935.

PMID:
19483157
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.

Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, Kaufman DS, Burns LJ, Slungaard A, McGlave PB, Wagner JE, Weisdorf DJ.

Biol Blood Marrow Transplant. 2008 Mar;14(3):282-9. doi: 10.1016/j.bbmt.2007.12.488.

PMID:
18275894
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk